Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

N > Transplant > Flashcards

Transplant Flashcards

1
Q

Diseases that can recur post-transplant?

A

Highest recurrence rates:

  1. Primary FSGS
  2. C3GN, DDD
  3. Atypical HUS
  4. IgA
  5. Membranous
  • Others:
    • Diabetic nephropathy
    • Primary Oxalosis if liver not transplanted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Transplant recipient contraindications?

A
  • Recent or metastatic cancer
  • Untreated current infection
  • Severe irreversible extrarenal disease
  • Recalcitrant treatment nonadherence
  • Psychiatric illness impairing consent and adherence
  • Current recreational drug abuse
  • Aggressive recurrent native kidney disease - ???
  • Limited, irreversible rehabilitative potential
  • Primary oxalosis
  • Uncorrectable chronic hypotension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Contraindications to deceased donation?

A
  • Most cancers
    • Apart from non-melanoma skin cancer or small RCC that can be resected at time of transplant, most are contraindicated
  • Certain infections
    • Severe, multifocal, difficult to treat
    • Active HIV
    • Severe fungal
    • Viral - Measles, adenovirus
  • Prion disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Banff criteria for acute antibody-mediated rejection?

A

Need all of:

  1. No AMR chronicity criteria met
  2. AMR activity criteria (any of):
    • g >0
    • ptc >0
    • v >0
    • Acute TMA in the absence of other cause
    • ATN in the absence of other cause
  3. Antibody interaction with tissue (any of):
    • +C4d
    • g+ptc >=2
    • increased expression of validated gene transcripts/classifiers in biopsy tissue strongly correlated with AMR
  4. +DSA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is exceptional distribution?

A

= “increased risk distribution”. NOT about kidney quality and more about social history/med history of donor.

  • Unknown travel history, ?TB ?Zika
  • Remote history of low risk cancer
  • Infection that can be treated
  • High risk sexual or substance use behavior
  • MSM
  • IVDU
  • Sex worker
  • Jail
  • Lived somewhere with high risk of infections
  • Neurodegenerative disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is expanded criteria (ECD)?

A
  • Age >= 60 or
  • Age >= 50 and 2 out of 3 of:
    • HTN
    • Death from stroke
    • Cr >132
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Transplant list exceptions/prioritization criteria?

A
  • Pediatric (growth retardation)
  • Medical emergency
  • Uremic cardiomyopathy
  • Lack of vascular access
  • 2 organs needed
  • HLA 6/6 match (too good of a match)
  • PRA>95%
  • If a living donor gets ESRD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment of ABMR?

A
  1. IVIG
  2. PLEX if +DSA
  3. Rituximab
  4. Steroids
  5. +/- eculizumab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What features make BKVN more likely (vs. ABMR)?

A
  • BK viremia >10,000 copies
  • +SV40
  • Intranuclear viral inclusions in renal tubular nuclei
  • Decoy cells in urine
  • More likely medullary inflammation as opposed to cortex
  • Ureteral stenosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does BKVN usually present?

A

Asymptomatic rise in creatinine during the 1st year post-transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Biopsy findings for diagnosis of BKVN?

A
  • Allograft biopsy shows BK viral inclusions in renal tubular nuclei and glomerular parietal epithelium. Intersititial mononuclear inflammation (plasma cell-rich), focal tubulitis. SV40 positive.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment algorithm/options for BKVN?

A
  • Reduce CNI
  • Reduce anti-metabolite
  • Reduce both CNI and anti-metabolite
  • Change tac to cyclosporine or sirolimus
  • Switch MMF to AZA or leflunomide
  • Other alternatives: cidofovir, quinolone, IVIG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Renal allocation system considerations

A
  1. Prioritization – multiple organ, children, medical urgency
  2. Age matching
  3. Waiting time
  4. Sharing within national registry
  5. Seek to avoid wasting organs
  6. Not be based on patients’ residence
  7. Testing to prevent the spread of infectious diseases
  8. Reduce inequalities from SES
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CMV prophylaxis - when and how long?

A
  • Donor - / Recipient – No treatment
  • Donor + / Recipient – Valganciclovir x 6mos (CMV mismatch)
  • Donor - / Recipient + Valganciclovir x 3 months (If induction with thymoglobulin x 6mos)
  • Donor + / Recipient + Valganciclovir x 3 months (If induction with thymoglobulin x 6mos)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Immediate and long-term complications of living kidney donation

A
  • Immediate complications
    • Surgical complications – Pain, bleeding, infection, risk of laceration to another organ, PE/DVT, hospital-acquired illnesses
    • Time away from work, financial loss
    • Psychosocial – fear, anxiety, depression
  • Longterm complications
    • Increased risk of proteinuria
    • Increased risk of HTN
    • No effect on fertility or outcome of future pregnancies (preterm delivery or low birth weight), but greater incidence of pre-eclampsia (11% in donors compared to 5% in matched no-donors). Therefore, advisable to delay pregnancy for up to at least 6 months to allow for maximal compensatory hypertrophy of the single kidney.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Causes of anemia post-transplant (pharmacological and non-pharmacological)

A
  • Pharmacological
    • Immunosuppression: MMF, AZA, sirolimus, everolimus
    • Septra
    • Dapsone (hemolytic anemia)
    • Discontinuation of EPO therapy
  • Non-pharmacological
    • Post-op bleeding
    • Iron deficiency
    • Infection eg. parvovirus
    • Tertiary hyperparathyroidism
    • Occult GIB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Causes of graft loss after 1 year?

A
  1. Chronic antibody rejection
  2. CNI toxicity
  3. Native disease recurrence
  4. BK nephropathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

3 antigen-presenting cells

A
  1. Macrophages
  2. Dendritic
  3. B lymphocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Pathologic features of chronic CNI toxicity

A
  • arteriolar hyalinosis, then progresses to obliterative arteriolopathy (suggesting primary endothelial damage) – both afferent and efferent arterioles are affected as compared with diabetes having usually only afferent hyalinosis
  • ischemic collapse or scarring of the glomeruli,
  • vacuolization of the tubules,
  • global and focal segmental glomerulosclerosis,
  • focal areas of IFTA (producing a picture of “striped” fibrosis).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How do CNI’s cause nephrotoxicity

A
  • Renal vasoconstriction / afferent arteriole
  • Interstitial fibrosis
  • TMA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Risk factors for developing diabetes post-transplant

A
  1. Obesity (RR 1.7)
  2. Older age >60 (RR 2.6)
  3. Black/Hispanic (RR 1.7)
  4. Hep C (RR 1.3)
  5. Immunosuppression with steroids, CNI (Tac RR 1.3), sirolimus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

MMF in pregnancy?

A
  • Black box warning: number of reports of 1st trimester pregnancy loss and congenital fetal abnormalities (face and ear).
  • Stop months before attempting conception. Must be off minimum 6 weeks (washout period), but usually 3 months to ensure new immunosuppressive regimen stable.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What immunosuppression meds are safe and not safe in pregnancy?

A

Safe: prednisone (note: high dose a/w cleft lip), CNI, azathioprine

Not safe: MMR, sirolmius, belatacept

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What criteria to consider to decrease risk of pregnancy in transplant recipents?

A
  • >1 year post-transplant
  • Serum Cr <133
  • No recent episodes of acute rejection
  • Normotensive or minimal antihypertensive regimen
  • Minimal or no proteinuria (<500 mg/day)
  • Normal allograft ultrasound
  • Pregnancy-safe drug regimen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Active CMV infection vs. CMV disease?

A
  • Active CMV infection – CMV viremia (with or without symptoms) (~5000)
  • CMV disease – CMV viremia + clinical manifestations of CMV disease (CMV syndrome OR tissue-invasive CMV disease)
    • CMV syndrome – CMV viremia + attributable symptoms/signs (fever, arthralgia, leukopenia, thrombocytopenia, etc.)
    • Tissue-invasive CMV disease – End-organ disease (eg. enteritis, colitis, hepatitis, nephritis, pneumonitis, meningitis, encephalitis, retinitis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

When to treat CMV in transplant, how, and how long?

A
  • Management:
    • Active CMV infection – Stop antimetabolite, monitor PCR. If continued replication, start antiviral.
    • CMV disease
      • Stop antimetabolite
      • Start antivirals
        • IV ganciclovir 5mg/kg q12h for severe disease, or
        • Oral valganciclovir 900 mg bid (adjust for kidney fxn)
      • CMV PCR weekly x 4 weeks
    • Duration of treatment: Usually 3 weeks. Treat until no CMV viremia in 2 PCRs, 1 wk apart. May be longer for more severe disease.
    • Secondary prophylaxis for 1-3 months (valgan 900 mg daily)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

HLA desensitization protocol?

A
  • IVIG (immunomodulation of recipient)
  • Rituximab (deplete B cells responsiblefor anti-HLA antibody production)
  • PLEX (removal of anti-HLA antibodies)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Window period for HIV, Hep C, HepB in the setting of exceptional distribution?

A

For NAT testing:

HIV - 5-6 days

Hep C - 3-5 days

Hep B - 20-22 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Transplant tourism cons?

A
  1. Compared to local donation, increased risk of infections
  2. Increased risk of graft loss
  3. Increased risk of mortality
  4. Increased risk of adverse outcomes for living donor and unethical
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Pros/cons of basiliximab vs. ATG

A
  • Basilximab (IL-2 antibody)
    • Lower risk of opportunistic infection and malignancy
    • Use if rabbit allergy
  • ATG
    • Decreased risk of DGF
    • Use for highly sensitized
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Cytotoxic vs. Flow cytometry cross-match?

A
  • Cytotoxic: Recipent serum + Donor lymphocytes + Complement
    • Cell lysis if positive
    • Specific but not sensitive
  • Flow: Recipient serum + Donor lymphocytes + Fluroscent antibodies that binds al human IgG
    • Run through machine to see signal strength
    • Sensitive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

T and B cell cross-match interpretation:

T cell neg, B cell neg

T cell pos, B cell neg

T cell neg, B cell pos

T cell pos, B cell pos

A

T cell neg, B cell neg - NEGATIVE XMatch

T cell pos, B cell neg - POSITIVE Class I

T cell neg, B cell pos - POSITIVE Class II antibodies

T cell pos, B cell pos - POSITIVE Class I and II

(T cells express Class I, B cells express both Class I and II)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

KDPI

A

KDPI (Kidney Donor Profile Index) - <85% okay, >85% higher risk

The KDPI is derived from the kidney donor risk index (KDRI) score and is the percentage of donors in a reference population that have a KDRI score less than or equal to the donor’s KDRI score.

The KDRI estimates the relative risk of posttransplant graft failure and is calculated from the donor age, ethnicity, creatinine, history of hypertension or diabetes, cause of death, height, weight, hepatitis C virus (HCV) status, and whether the kidney was donated after circulatory death.

34
Q

Risk factors for PTLD

A

EBV mismatch

Younger age at transplant (EBV-naive)

ATG (prolonged or repeated doses)

Degree of immunosuppression

First year of transplant (highest immunosuppression)

History of pre-transplant malignancy

Fewer HLA matches

35
Q

Risk factors for acute antibody-mediated rejection

A
  1. Preexisting sensitization due to blood transfusion, prior transplant, pregnancy
  2. PRA >80%
  3. High degree of HLA-mismatch
  4. Positive B-cell crossmatch
  5. Patients with donor specific antibodies
  6. ABO incompatibility
  7. Steroid minimization
  8. Non-compliant with immunosuppression
  9. African American recipient
  10. Previous rejection episodes
36
Q

Risk factors for NODAT

A
  • Pre-transplant impaired fasting glucose, perioperative hyperglycemia
  • FHx T2DM
  • Hx of gestational DM
  • Obesity
  • Older age >60
  • African American/Hispanic
  • Hep C
  • Immunosuppression with steroids, CNI (Cyclosporine and Tac), sirolimus
37
Q

2 reasons you would switch to sirolimus?

A

CNI-nephrotoxicity

CNI-neurotoxicity or TMA

BK nephropathy

Skin cancer

38
Q

Pathologic findings of chronic allograft nephropathy

A
  • interstitial fibrosis and tubular atrophy (IFTA)
  • double contouring of GBM
  • subintimal vessel wall thickening
39
Q

Risk factors for chronic allograft nephropathy

A
  • Acute rejection
  • Hypertension
  • Glomerular hyperfiltration and hypertrophy
  • Superimposed recurrent or de novo kidney parenchymal disease
  • Delayed graft function
  • Hyperlipidemia
40
Q

How does chronic allograft nephropathy usually present?

A

Slow, progressive decrease in kidney function, usually associated with hypertension and worsening proteinuria

41
Q

Treatment of acute T-cell mediated rejection

A

Pulse steroids

Increase immunosuppression

ATG (if v lesion)

42
Q

Post-transplant patient with thigh pain and difficulty weight-bearing, normal xray. Diagnosis and 2 tests?

A

Avascular necrosis

MRI gold standard, bone scan (but not very sensitive)

43
Q

How long should a patient wait before being transplanted after the following malignancies: basal cell carcinoma, colon cancer, breast cancer

A
  • Basal cell – 0
  • Colon CA – 5
  • Breast CA – 5
  • Per guidelines, the following do NOT need waiting period:
    • Non-metastatic basal cell or squamous cell of skin
    • Melanoma in situ
    • Small RCC <3cm
    • Prostate cancer Gleason <=6
    • Carcinoma in situ (ductal, cervical)
    • Thyroid (papillary, follicular) <2cm, of low grade histology
    • Superficial bladder cancer
  • Others require waiting period depending on cancer
44
Q

Mechanism of action of MMF

A

Inhibits purine synthesis required for lymphocyte proliferation

45
Q

Mechanism of action for tacrolimus

A

Binds to FK-binding protein, which inhibits calcineurin. Calcineurin normally stimulates IL-2 transcription, so this inhibits IL-2 -> inhibits T-cell proliferation.

46
Q

Mechanism of ATG

A

Polyclonal IgG from horses or rabbits immunized with human thymocytes

They block T-cell membrane proteins and are cytotoxic, leading to depletion of peripheral lymphocytes

47
Q

Side effects/risks of ATG

A

Anaphylaxis from rabbit allergy

Cytokine-release syndrome (fever, hypotension, cytopenias, rare-capillary leak syndrome)

Serum sickness

Leukopenia, thrombocytopenia

PTLD, EBV activation

Infections - viral eg. CMV (hence why CMV proph)

48
Q

Mechanism of sirolimus, everolimus

A

Binds FKBP12 (which normally engages TOR protein) -> inhibition of TOR -> decrease cytokine-dependent cellular proliferation at the G1 to S phase of cell-division cycle

49
Q

Side effects of sirolimus

A
  1. Dyslipidemia
  2. HTN
  3. Delayed wound healing
  4. Proteinuria, progressive glomerulopathy (FSGS), AKI
  5. TMA
  6. Teratogenic
  7. Progressive interstitial pneumonitis
  8. Cytopenias (any)
  9. Peripheral edema
50
Q

Mechanism of action of azathioprine

A

Purine analogue incoporated into cellular DNA -> inhibits purine nucleotide synthesis

51
Q

What is the EPTS

A
  • Estimated Post Transplant Score (0-100%, lower score are better)
  • Score dependent on:
    • Prior transplant
    • DM
    • Time on dialysis
    • Age
  • EPTS =<20% recipients should receive kidneys with KDPI <=20%
52
Q

Meds that will decrease CNI levels

A
  • Anti-TB meds (rifampin, rifabutin, isoniazid)
  • Anti-consulvants (phenytoin, carbamazepine, barbiturates)
  • Cephalosporins
  • Imipenem
  • St. Johns wort
53
Q

Meds that will increase CNI levels

A
  • ABx - macrolides
  • CCB, non-dihydropyridine (eg. diltiazem)
  • Amiodarone
  • Antifugnals -azoles (eg. ketoconazole)
  • Anti-retrovirals - HIV protease inhibitors
  • mTOR inhibitors
54
Q

What is C4d?

A

C4d is a breakdown product of the classical complement pathway.

Binds to endothelial and collagent basement membrane (evidence antibody activity is or was present)

55
Q

4 steps of T cell activation

A
  • 1. Signal 1: Antigen-presenting cell presents antigen as a MHC-peptide complex to the T-cell receptor, transduced through the CD3 complex.
  • 2. Signal 2: Co-stimulation occurs when co-receptor proteins recognized by T-cells (CD80/86 on antigen-presenting cell engages CD28 on T-cells)
    1. Signal 1+2 stimulate 3 pathways:
      * Calcium/calcineurin pathway
      * RAS-MAP-kinase pathway
      * Nuclear factor-KB pathway
      * –> these lead to IL-2 and other cytokine expression
  • 4. Signal 3: IL-2 binds to its receptor, activating mTOR pathway, which triggers T-cell generation and amplification.
56
Q

What causes a high PRA?

A

Blood transfusions

Pregnancy

Prior transplants

57
Q

Definition of delayed graft function and its effect on longterm allograft function

A

Requirement of dialysis or oliguria within the first 7 days post-transplant

Associated with short and longterm allograft failure

58
Q

5 types of viral-associated malignancy that can occur post-transplant and associated virus?

A
  1. PTLD - EBV
  2. Adult T-cell lymphoma - HTLV
  3. Squamous cell (skin, cervix, etc) - HPV
  4. Kaposi sarcoma - HHV-8
  5. Merkel cell carcinoma - Merkel cell polyomavirus
  6. Liver cancer - HBV, HCV
59
Q

3 tests to detect CMV

A

CMV IgM and IgG antibody

CMV PCR

Histopathology/biopsy showing basophilic intranuclear inclusions

Shell vial culture

60
Q

Fresh post-transplant, initial good graft function then AKI with thrombocytopenia PLT 80 -> 30s

Diagnosis and management?

A
  • Diagnosis:
    • De-novo drug-induced TMA from CNI
  • Management:
    • Confirm TMA process with labs
    • Kidney biopsy
    • Check CNI levels first - if they are supra therapeutic, hold. If the levels are NOT high, you do NOT hold CNI. You try switching from cyclosporine to tac or vice versa.
    • Stop sirolmus if also on that.
    • Exclude other causes of TMA - complement panel, ADAMTS13, stool C&S
    • Assess for other causes of AKI - HLA, US, tac levels
    • Ensure viral work-up done for eculizumab (CMV, HIV, Parvo, BK)
    • If treating with eculizumab, ensure protection against meningococcal infections
    • PLEX if any concern for TTP or eculizumab not available
61
Q

Advantages and disadvantages of laparoscopic living kidney donation

A
  1. Advantages of laporoscopic living kidney donation
    1. Shorter post-op hospital stay
    2. Quicker return to work
    3. Less post-operative pain
    4. Minimal surgical score
    5. Magnified view of renal vessels
  2. Disadvantages of laporoscopic living kidney donation
    1. Pneumoperitoneum may compromise renal blood flow
    2. Longer OR time
    3. Tendancy to have shorter renal vessels and multiple arteries
    4. Impaired early graft function, but no difference at 6 months
    5. Increased risk of ureteral injury with multiple renal arteries
62
Q

Effect/benefits of MMF in glomerular disease

Benefit over cyclophosphamide?

A
  1. Decrease lymphocyte proliferation
  2. Decrease antibody production
  3. Impairs binding of lymphocytes to vascular endothelial cells by downregulating expression of adhesion molecules

Benefit over cyclophosphamide - is lymphocyte-specific, less infertility, malignancy

63
Q

Reasons why switch from cyclosporine to tacrolimus?

A

Tac superior for preservation of graft function (Symphony study)

Cyclosporine has some worse side effects: hirsutism, gingival hypertrophy

HTN worse with cyclosporine

Any rejection on cyclosporine

64
Q

What side effects are worse with tacrolimus than cyclosporine

A

Tremor, headache

NODAT

GI symptoms

Alopecia

65
Q

cyclosporine plus statin - how to prevent/manage potential rhabdo

A
  • As a result of cyclosporine-induced impairment in metabolism of the statin (cyclosporine is cytchromc P450 inhibitor)
  • Start at low dose, avoid lovastatin and simvastatin
    • Prava and fluvastatin better
  • Avoid coadministration of gemfibrozil/fibrates
  • Follow CK monthly
  • Inform patients of potential interaction and symptoms (myopathy)
66
Q

Define moderate tubulitis

A

Moderate tubulitis = 5-10 cells per tubular cross section in cortex (t2 per Banff Classification of renal allograft rejection)

67
Q

MSK problems after transplant?

A

Osteoporosis

AVN

Steroid myopathy

CNI myopathy

Statin myopathy

Persistent hyperparathyroidism

68
Q

When picking recipient for cadaveric kidney, 5 recipient-related factors that you consider?

A
  1. Increased time on waiting list (time on dialysis)
  2. 0 HLA mismatch
  3. Highly sensitized
  4. Limited vascular access options
  5. Previous living donor
  6. Pediatric
  7. Age match <15 years
  8. Multi-organ transplant
69
Q

Brother of pt with ADPKD living donor evaluation?

A

If age <40 and >=1 cyst on US/CT -> genetic testing

If age >=40 and >1 cyst on US/CT -> genetic testing

If age >=40 and only 1 cyst, rules out ADPKD

(UpToDate and KDIGO Living Donor guidelines)

70
Q

Antimicrobial prophylaxis for post-transplant

A
  • Surgical prophylaxis: Cefazolin IV at time of OR
  • PCP PPx: tmp-smx 1 DS MWF for 1 year
  • CMV PPx:
    • Donor - / Recipient – No treatment
    • Donor + / Recipient – Valganciclovir x 6mos (CMV mismatch)
    • Donor - / Recipient + Valganciclovir x 3 months (If induction with thymoglobulin x 6mos)
    • Donor + / Recipient + Valganciclovir x 3 months (If induction with thymoglobulin x 6mos)
  • Nystatin x 1 mo
  • Vaccines:
    • Wait 3-6 months before any vaccines
    • Annual influenza, Pneumococcus q 5 years
    • Routine vaccine schedule, but no live vaccines
    • Hepatitis B vaccine pre-transplant
71
Q

Most common skin cancer post-transplant

Management?

A
  • Squamous cell carcinoma
  • (Other skin cancers: basal cell, melanoma, Kaposi sarcoma, Merkel cell carcinoma)
  • Management:
    • Reduction of immunosuppression
    • Switch CNI to mTOR inhibitor (sirolimus)
    • MMF better than AZA
72
Q

Pt who is 36h post-Tx w/ Cr 170 to 195 and U/S shows hydro. What to arrange?

A
  • Early hydronephrosis post-transplant
    • UVJ stenosis is most common site of obstruction
    • DDx:
      • 1) Blood clot in the ureter, bladder, or catheter
      • 2) Kinked ureter
      • 3) Incorrect suture placement
    • Management:
      • Gentle bladder irrigation with 3-way foley
      • Consult urology to work-up stent thrombosis/obstruction/stenosis
      • In olden days, pre-stents: Nephrostomy → antegrade pyelogram
73
Q

Management of CNI-induced TMA post-transplant

A
  • Confirm TMA process with labs
  • Kidney biopsy
  • Check CNI levels first - if they are supra therapeutic, hold. If the levels are NOT high, you do NOT hold CNI. You try switching from cyclosporine to tac or vice versa.
  • Stop sirolmus if also on that.
  • Exclude other causes of TMA - complement panel, ADAMTS13, stool C&S
  • Ensure viral work-up done for eculizumab (CMV, HIV, Parvo, BK)
  • If treating with eculizumab, ensure protection against meningococcal infections
74
Q

Minimum GFR to donate kidney?

A

Per KDIGO 2020 Living donor guidelines:
eGFR:
>90 OK
60-90 individualized
<60 should not donate

Albuminuria:
ACR <3
ACR 3-10 individualized
ACR >10 should not donate

Hematuria:
If reversible cause, OK
If due to IgA, should not donate

(Amsterdam guidelines: eGFR >80)

75
Q

6mos post-Tx on MMF, tacrolimus, Septra, prednisone, ranitidine, diltiazem. Stable Cr at 220. K=6.1. 3 reasons for hyperK?

A
  1. Hyperkalemia post transplant
    1. Tacrolimus (impairs potassium secretion in the cortical collecting duct)
    2. Septra (ENaC blocker)
      1. Trimethoprim (an organic cation) acts like amiloride and blocks apical membrane sodium channels in the mammalian distal nephron. As a consequence, the transepithelial voltage is reduced and potassium secretion is inhibited. Decreased renal potassium excretion secondary to these direct effects on kidney tubules leads to hyperkalemia in a substantial number of patients being treated with trimethoprim-containing drugs
    3. Diltiazem increases CNI levels, which may contribute to the CNI nephrotoxicity
    4. Decreased GFR and poor dietary compliance
76
Q

Anti-GBM disease after transplantation in Alport’s disease - how often does this occur and why?

Incidence of graft loss in these patients?

A

<5%

Alport’s have a defect in their type IV collagen, leading to an altered Goodpasture antigen. The donor kidney has a normal antigen that was previously “unseen” by the recipient, potentially causing an immune response -> anti-GBM antibodies.

Of those who get anti-GBM, ~75% lose graft

77
Q

Risk factors for DGF?

A
  1. Prolonged cold ischemia time
  2. Donor >50 years of age
  3. Peak PRA >50%, HLA mismatch
  4. Donor brain death
  5. Donor acute renal dysfunction
  6. Recipient factors: obesity, dm
78
Q

Causes of hypophosphatemia early post-transplant?

A
  • Persistent hyperparathyroidism
  • High FGF-23
  • Massive initial diuresis
  • Osmotic diuresis from glucosuria
  • Impaired phosphate reabsorption from ischemic injury
  • Steroids (inhibit proximal reabsorption)
  • Continued phosphate binders
  • Malnutrition
79
Q

Side effects with MMF

A

GI, cytopenias, pregnancy (1st trimester loss and malformations like cleft palate, heart/kidney/limb/esophagus anomalies), infection, malignancy

80
Q

Side effects with rituximab

A

Infusion reaction (can be anaphylactic, occur during first infusion), decrease response to vaccines, hypogammaglobulinemia, infection, HepB reactivation, PML

81
Q

Indications for combined kidney liver transplant

A

Candidate for liver transplant plus:

  • CKD
    • on regular dialysis
    • GFR <=35
  • Sustained AKI
    • Dialysis x6 weeks at least
    • GFR <=25 x 6 weeks at least
  • Metabolic disease
    • Primary hyperoxalosis
    • Familial nonneuropathic systemic amyloid
    • Inborn errors of metabolism - methylmalonic aciduria

N (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions